Age related macular degeneration 8
disease diseaseOn this page
Also known as age related macular degeneration type 8age-related macular degeneration caused by mutation in ARMS2ARMD8ARMS2 age-related macular degenerationmacular degeneration, age-related, 8macular Degeneration, age-related, type 8
Summary
Age related macular degeneration 8 (MONDO:0013416) is a disease with 3 cohort genes.
At a glance
- Cohort genes: 3
- ClinVar variants: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | age related macular degeneration 8 |
| Mondo ID | MONDO:0013416 |
| OMIM | 613778 |
| DOID | DOID:0110020 |
| UMLS | C3151070 |
| MedGen | 462420 |
| GARD | 0024923 |
| Is cancer (heuristic) | no |
Also known as: age related macular degeneration type 8 · age-related macular degeneration caused by mutation in ARMS2 · ARMD8 · ARMS2 age-related macular degeneration · macular degeneration, age-related, 8 · macular Degeneration, age-related, type 8
Data availability: 22 ClinVar variants · 1 GenCC gene-disease record.
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › macular degeneration › degeneration of macula and posterior pole › age-related macular degeneration › age related macular degeneration 8
Related subtypes (14): wet macular degeneration, age related macular degeneration 2, age related macular degeneration 1, macular degeneration, age-related, 3, age related macular degeneration 7, age related macular degeneration 4, age related macular degeneration 9, age related macular degeneration 10, age related macular degeneration 11, age related macular degeneration 6, age related macular degeneration 12, age related macular degeneration 14, macular dystrophy with central cone involvement, dry age related macular degeneration
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
22 retrieved; paginated sample, class counts are floors:
7 uncertain significance, 5 benign/likely benign, 5 likely benign, 4 benign, 1 risk factor
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 980 | NC_000010.11:g.122457305_122457748delinsTTATTAATTAATTAACTAAAATTAAATTATTTAGTTAATTTAATTAACTAAACT | ARMS2 | risk factor | no assertion criteria provided |
| 299037 | NM_001099667.3(ARMS2):c.*251T>C | ARMS2 | Uncertain significance | criteria provided, single submitter |
| 880000 | NM_001099667.3(ARMS2):c.*313G>C | ARMS2 | Uncertain significance | criteria provided, single submitter |
| 880002 | NM_001099667.3(ARMS2):c.*399A>G | ARMS2 | Uncertain significance | criteria provided, single submitter |
| 299027 | NM_001099667.3(ARMS2):c.-60G>T | HTRA1-AS1 | Uncertain significance | criteria provided, single submitter |
| 299034 | NM_001099667.3(ARMS2):c.*15A>G | HTRA1-AS1 | Uncertain significance | criteria provided, single submitter |
| 878185 | NM_001099667.3(ARMS2):c.23C>T (p.Pro8Leu) | HTRA1-AS1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 878186 | NM_001099667.3(ARMS2):c.39G>A (p.Ala13=) | HTRA1-AS1 | Uncertain significance | criteria provided, single submitter |
| 299029 | NM_001099667.3(ARMS2):c.112C>T (p.Arg38Ter) | ARMS2 | Benign | criteria provided, multiple submitters, no conflicts |
| 299031 | NM_001099667.3(ARMS2):c.298-13A>G | ARMS2 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 299032 | NM_001099667.3(ARMS2):c.298-13A>T | ARMS2 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 299036 | NM_001099667.3(ARMS2):c.*204C>A | ARMS2 | Likely benign | criteria provided, single submitter |
| 299038 | NM_001099667.3(ARMS2):c.*373T>G | ARMS2 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 878184 | NM_001099667.3(ARMS2):c.-9G>A | ARMS2 | Likely benign | criteria provided, single submitter |
| 879637 | NM_001099667.3(ARMS2):c.*45T>G | ARMS2 | Likely benign | criteria provided, multiple submitters, no conflicts |
| 879638 | NM_001099667.3(ARMS2):c.*107T>G | ARMS2 | Likely benign | criteria provided, multiple submitters, no conflicts |
| 979 | NM_001099667.3(ARMS2):c.205G>T (p.Ala69Ser) | ARMS2 | Benign | criteria provided, multiple submitters, no conflicts |
| 299028 | NM_001099667.3(ARMS2):c.8G>A (p.Arg3His) | HTRA1-AS1 | Benign | criteria provided, multiple submitters, no conflicts |
| 299035 | NM_001099667.3(ARMS2):c.*161C>T | HTRA1-AS1 | Likely benign | criteria provided, single submitter |
| 299039 | NM_001099667.3(ARMS2):c.*376T>C | HTRA1-AS1 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 299041 | NM_001099667.3(ARMS2):c.*385A>C | HTRA1-AS1 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 880001 | NM_001099667.3(ARMS2):c.*374G>T | HTRA1-AS1 | Benign | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 1 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| ART4 | Moderate | Autosomal recessive | age related macular degeneration 8 |
Cohort genes → proteins
3 cohort genes, 2 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 3 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| ART4 | HGNC:726 | ENSG00000111339 | Q93070 | Ecto-ADP-ribosyltransferase 4 | gencc |
| ARMS2 | HGNC:32685 | ENSG00000254636 | P0C7Q2 | Age-related maculopathy susceptibility protein 2 | clinvar |
| HTRA1-AS1 | HGNC:58122 | ENSG00000285955 | HTRA1 and ARMS2 antisense RNA 1 | clinvar |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 3 | 1.8× | 0.174 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| ART4 | Other/Unknown | no | ART, ADP-ribosyltransferase_ARG | |
| ARMS2 | Other/Unknown | no | ||
| HTRA1-AS1 | Other/Unknown | no |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 3 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| left ovary | 2 |
| primordial germ cell in gonad | 2 |
| liver | 1 |
| right coronary artery | 1 |
| right lobe of liver | 1 |
| placenta | 1 |
| cortical plate | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| ART4 | 161 | broad | marker | liver, right lobe of liver, right coronary artery |
| ARMS2 | 99 | tissue_specific | yes | primordial germ cell in gonad, placenta, left ovary |
| HTRA1-AS1 | 112 | yes | primordial germ cell in gonad, cortical plate, left ovary |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ARMS2 | 461 |
| ART4 | 301 |
| HTRA1-AS1 | 0 |
Structural data
PDB: 0 · AlphaFold-only: 2 · No structure: 1
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| ART4 | Q93070 | 81.00 |
| ARMS2 | P0C7Q2 | 58.14 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 3 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Post-translational modification: synthesis of GPI-anchored proteins | 1 | 167.9× | 0.018 | ART4 |
| Post-translational protein modification | 1 | 19.2× | 0.078 | ART4 |
| Metabolism of proteins | 1 | 12.4× | 0.081 | ART4 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| arginine metabolic process | 1 | 1203.7× | 0.002 | ART4 |
| retina homeostasis | 1 | 561.7× | 0.002 | ARMS2 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3
Druggability breadth: 0 of 3 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| ART4 | 0 | 0 |
| ARMS2 | 0 | 0 |
| HTRA1-AS1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 3 | ART4, ARMS2, HTRA1-AS1 |
Undrugged target profiles
3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| ART4 | 0 | — |
| ARMS2 | 0 | — |
| HTRA1-AS1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.